Endpoints News 2025년 12월 19일 Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail
Endpoints News 2025년 12월 19일 Joe Jimenez's Aditum goes to Fosun for major biobuck-loaded collaboration
Endpoints News 2025년 12월 18일 Daiichi and Merck's I-Dxd lung cancer study faces partial hold due to deaths
Endpoints News 2025년 12월 18일 After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset
Endpoints News 2025년 12월 18일 Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
Endpoints News 2025년 12월 18일 Steve Paul's post-Karuna act draws $165M to schizophrenia biotech Syremis